Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment

Inicio | ¿Qué es? | Contacto

English | Català

Consultar RECERCAT

Por comunidades y
colecciones Por fecha Por autores Por títulos Por temas (CDU)

Consultar departamento

Por fecha Por autores Por títulos Por temas (CDU)

Estadisticas

Del documento Todo RECERCAT

Mi RECERCAT

Entrar Alertas por correo-e

Directorio de otros repositorios

RECERCAT Principal > Universitat de Girona > Documents de recerca > Visualizar documento

Para acceder a los documentos con el texto completo, por favor, siga el siguiente enlace: http://hdl.handle.net/10256/8264

dc.contributor.author	Oliveras Ferrarós, Cristina
dc.contributor.author	Massaguer i Vall-llovera, Anna
dc.contributor.author	Vázquez Martín, Alejandro
dc.contributor.author	Carrion Salip, Dolors
dc.contributor.author	Queralt, Bernardo
dc.contributor.author	Cufí González, Sílvia
dc.contributor.author	Martin Castillo, Begoña
dc.contributor.author	Bosch Barrera, Joaquim
dc.contributor.author	Brunet i Vidal, Joan
dc.contributor.author	Llorens Duran, Rafael de
dc.contributor.author	Menéndez Menéndez, Javier Abel
dc.date	2013-09-19T10:37:00Z
dc.date	2013-09-19T10:37:00Z
dc.date	2012
dc.identifier.citation	1021-335X (versió paper)
dc.identifier.citation	1791-2431 (versió electrònica)
dc.identifier.citation	018316
dc.identifier.uri	http://hdl.handle.net/10256/8264
dc.format	application/pdf
dc.language.iso	eng
dc.publisher	Spandidos Publications
dc.relation	http://dx.doi.org/10.3892/or.2012.1732
dc.relation	Reproducció digital del document publicat a: http://www.spandidos-publications.com/or/27/6/1887
dc.relation	© Oncology Reports, 2012, vol. 27, núm. 6, p. 1887-1892
dc.relation	Articles publicats (D-B)
dc.rights	Tots els drets reservats
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	Càncer -- Tractament
dc.subject	Cancer -- Treatment
dc.subject	Recte -- Càncer
dc.subject	Rectum -- Cancer
dc.subject	Medicaments antineoplàstics
dc.subject	Antineoplastic agents
dc.title	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.description.abstract	The recent identification of HER2 gene amplification as a novel predictor of resistance to the EGFR (HER2)-targeted antibody cetuximab and of response to combination therapies against EGFR and HER2 in wild-type KRAS tumor settings may represent a further step toward personalized medicine for patients with colorectal cancer. Herein, we show that transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification is a molecular phenomenon that takes place in EGFR-dependent, wild-type KRAS squamous cell carcinoma (SCC) cells that acquire resistance to cetuximab. Since cetuximab activity against cetuximab-refractory SCC cells can be fully restored in the presence of the anti-HER2 monoclonal antibody trastuzumab, our findings suggest that, beyond HER2 gene amplification, we might need to redefine the threshold values for HER2 positivity to improve the accuracy of the selection of cetuximab-refractory patients with wild-type KRAS that may benefit from receiving a cetuximab/trastuzumab combination

Mostrar el registro sencillo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: A pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models

Oliveras Ferrarós, Cristina; Vázquez Martín, Alejandro; Queralt, Bernardo; Adrados, Manuel; Ortiz, Rosa; Cufí González, Sílvia; Hernández Yagüe, Xavier; Guardeño, Raquel; Báez, Luciana; Martin Castillo, Begoña; Pérez Martínez, Maria Carmen; López Bonet, Eugeni; Llorens Duran, Rafael de; Bernadó, Luis; Brunet i Vidal, Joan; Menéndez Menéndez, Javier Abel

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer

Queralt, Bernardo; Cuyàs, Elisabet; Bosch Barrera, Joaquim; Massaguer i Vall-llovera, Anna; Llorens Duran, Rafael de; Martin Castillo, Begoña; Brunet i Vidal, Joan; Salazar, Ramon; Menéndez Menéndez, Javier Abel

Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts

Cufí González, Sílvia; Corominas Faja, Bruna; Vázquez Martín, Alejandro; Oliveras Ferrarós, Cristina; Dorca Ribugent, Joan; Bosch Barrera, Joaquim; Martin Castillo, Begoña; Menéndez Menéndez, Javier Abel

Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling

Oliveras Ferrarós, Cristina; Vázquez Martín, Alejandro; Colomer, Ramon; Llorens Duran, Rafael de; Brunet i Vidal, Joan; Menéndez Menéndez, Javier Abel

Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment

Menéndez Menéndez, Javier Abel; Quirantes Piné, Rosa; Rodríguez Gallego, Esther; Cufí González, Sílvia; Corominas Faja, Bruna; Cuyàs, Elisabet; Bosch Barrera, Joaquim; Martin Castillo, Begoña; Segura Carretero, Antonio; Joven, Jorge

Accesibilidad | Aviso legal | Política de Cookies | Documentos de uso interno

Coordinación

Patrocinio